These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 20683031)

  • 1. Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
    Saif MW; Syrigos K; Penney R; Kaley K
    Anticancer Res; 2010 Jul; 30(7):2905-9. PubMed ID: 20683031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
    Ko AH; Truong TG; Kantoff E; Jones KA; Dito E; Ong A; Tempero MA
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):875-81. PubMed ID: 23053263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer.
    Cereda S; Reni M
    J Chemother; 2008 Aug; 20(4):509-12. PubMed ID: 18676234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.
    Soares HP; Bayraktar S; Blaya M; Lopes G; Merchan J; Macintyre J; Mayo C; Green MR; Silva O; Levi J; Walker G; Rocha-Lima CM
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):839-45. PubMed ID: 24562589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward.
    Ramfidis VS; Psyrri A; Syrigos KN; Saif MW
    JOP; 2014 Jul; 15(4):286-8. PubMed ID: 25076321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma.
    Ajouz H; Mukherji D; Haydar A; Yakan AS; Saleh A; Elias E; Temraz S; Faraj W; Khalife M; Shamseddine A
    J Gastrointest Cancer; 2014 Mar; 45(1):109-12. PubMed ID: 24362621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.
    De Jesus-Acosta A; Oliver GR; Blackford A; Kinsman K; Flores EI; Wilfong LS; Zheng L; Donehower RC; Cosgrove D; Laheru D; Le DT; Chung K; Diaz LA
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):415-24. PubMed ID: 21800112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
    Kulke MH; Blaszkowsky LS; Ryan DP; Clark JW; Meyerhardt JA; Zhu AX; Enzinger PC; Kwak EL; Muzikansky A; Lawrence C; Fuchs CS
    J Clin Oncol; 2007 Oct; 25(30):4787-92. PubMed ID: 17947726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
    Reni M; Cereda S; Rognone A; Belli C; Ghidini M; Longoni S; Fugazza C; Rezzonico S; Passoni P; Slim N; Balzano G; Nicoletti R; Cappio S; Doglioni C; Villa E
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):115-23. PubMed ID: 21626049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas.
    Hill ME; Li X; Kim S; Campbell A; Culler K; Bloomston M; Zalupski M; Hejna G; Bekaii-Saab T
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):511-7. PubMed ID: 20461379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
    Reni M; Cereda S; Mazza E; Passoni P; Nicoletti R; Balzano G; Zerbi A; Arcidiacono PG; Staudacher C; Di Carlo V
    Am J Clin Oncol; 2008 Apr; 31(2):145-50. PubMed ID: 18391598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
    Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
    J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
    Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
    Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
    Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.
    Dakik HK; Moskovic DJ; Carlson PJ; Tamm EP; Qiao W; Wolff RA; Abbruzzese JL; Fogelman DR
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):425-30. PubMed ID: 21850466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
    Ko AH; Dito E; Schillinger B; Venook AP; Bergsland EK; Tempero MA
    Cancer Invest; 2008 Feb; 26(1):47-52. PubMed ID: 18181045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.
    Fine RL; Fogelman DR; Schreibman SM; Desai M; Sherman W; Strauss J; Guba S; Andrade R; Chabot J
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):167-75. PubMed ID: 17440727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival benefit with the combination of docetaxel, gemcitabine and erlotinib in advanced and/or metastatic pancreatic cancer patients.
    Samelis GF; Ekmektzoglou K; Tsiakou A; Giannakaki S; Konstadoulakis M
    Hepatogastroenterology; 2011; 58(110-111):1776-81. PubMed ID: 21940348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma.
    Sherman WH; Chu K; Chabot J; Allendorf J; Schrope BA; Hecht E; Jin B; Leung D; Remotti H; Addeo G; Postolov I; Tsai W; Fine RL
    Cancer; 2015 Mar; 121(5):673-80. PubMed ID: 25492104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.
    Katopodis O; Polyzos A; Kentepozidis N; Giassas S; Rovithi M; Bozionelou V; Kalbakis K; Vamvakas L; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):361-8. PubMed ID: 20428874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.